Home healthcare Diabetes flash monitoring device using a novel sensor that is simple to use and fully non-invasive, combined with Lifestyle phone app to target the obesity which leads to Type 2 diabetes

肥胖通常会导致2型糖尿病，这种疾病被认为是感染COVID-19最严重形式的特别风险。糖尿病还与许多慢性限制生命的并发症有关，如心力衰竭、视力丧失和截肢。在英国460万糖尿病患者中，2型糖尿病占90%。当患者对他们的生活方式做出相对较小但意义重大的改变时，这种情况通常可以得到很好的控制甚至逆转。控制这种情况需要定期测量血液中的血糖水平。英国糖尿病协会表示，2型糖尿病患者在获得良好控制病情所需的必要检测设备方面得不到很好的服务。当设备可用时，通常是较旧的不太有效的类型，而不是向1型患者提供较新的更昂贵的系统。这种节省成本的措施是非常短视的，因为2型糖尿病患者对及时干预反应良好，并防止患者继续发展不愉快的，昂贵的治疗，慢性并发症。泽莱米克有限公司（Zelemiq Ltd.）设计了一种基于可行性研究的新血糖监测仪，它有望提供与目前为1型糖尿病患者保留的更好的新系统相同的控制水平，但价格与目前为2型糖尿病患者提供的价格相当。该系统的优点是完全非侵入性，避免了穿刺皮肤来读取血糖水平的需要。所有现有的方法都需要刺穿皮肤。Zelemiq的新传感器设计将通过一个手机应用程序来增强，该应用程序将作为系统的用户界面。该应用程序将用于鼓励生活方式的改变，使患者能够管理他们的状况。例如，当血糖过高时，它会发出警报，鼓励佩戴者避免某些食物并进行一些锻炼。佩戴者将获得奖励，即能够追踪他们的身体状况在短期和长期内的改善情况。佩戴者将能够使用该设备了解他们的血糖水平在一天中的变化情况，并以此来更好地管理他们的进食时间和食物。世界卫生组织表示，如果目前的趋势继续下去，到2030年全球将有4.38亿糖尿病患者。通过制造一种价格合理、使用方便的系统，使糖尿病患者能够正确地监测和管理他们的糖尿病，Zelemiq希望看到这一趋势得到扭转。

Obesity routinely leads to Type 2 Diabetes, a disease identified as giving a particular risk for contracting the worst forms of COVID-19, Diabetes is also associated with a number of chronic life limiting complications such a, heart failure, sight loss, and amputation of limbs . Type 2 accounts for 90% of the 4.6M Diabetes cases in the UK. The condition can usually be well manged or even reversed when the sufferers make relatively small but significant changes to their lifestyle. Managing the condition requires making regular measurements of the sugar levels in the blood. Diabetes UK say that Type 2 sufferers are being poorly served with provision of the necessary test equipment needed to achieve good control of their condition. When equipment is made available, it is usually of an older less effective type, than the newer more expensive systems excursively going to Type 1 sufferers. This cost savings measure is very short sighted, because Type 2 Diabetes responds well to timely intervention and prevents the sufferer from going on to develop the unpleasant, and costly to treat, chronic complications.Zelemiq Ltd. has a new design of blood sugar monitor which has based feasibility study that promises to offer the same levels of control as the better newer systems current reserved for Type 1 sufferers, but at a price which rivals the cost the provision current made to Type 2 sufferers. The system has the advantage of being entirely non-invasive by avoiding the need to puncture the skin to take readings of blood sugar levels. All existing methods require the skin to be punctured.Zelemiq's new sensor design will be augmented by a phone app which will act as the user interface for the system. This application will be used to encourage the lifestyle changes that will enable the sufferer to manage their condition. It will, for instance, be used to alert when blood sugar is high and encourage the wearer to avoid certain foods and take some exercise, they will be rewarded by being able to track how their condition improves in the short term and over time. The wearer will be able use the device to learn how their blood sugar levels change across the day and use this to better manage when and what they eat.The World Health Organisation say that by 2030 there will be 438M Diabetes sufferers globally if current trend continue. By making an affordable easy to use system available, that enables diabetics to properly monitor and so manage their Diabetes, Zelemiq hopes to see this trend reversed.